文献速递心力衰竭与心肌病

RESTAGE-HF研究:左心室辅助装置联合药物逆转重构实现心肌恢复的中期与主要终点结果

Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results.
PubMed 文献 · Circulation · 2020-10-26

RESTAGE-HF是一项前瞻性多中心非随机研究,纳入40例非缺血性心肌病晚期心衰患者,接受HeartMate II左心室辅助装置(LVAD)并优化卸载联合标准化药物治疗和规律功能测试,40%(16/40)达到主要终点,接受方案者中50%在18个月内符合移除标准且12个月无移植/装置/死亡。

要点

  • 优化LVAD卸载联合标准化药物逆转重构治疗可提高晚期心衰患者心肌恢复和LVAD移除率。
  • 接受方案的患者中50%(18/36)在18个月内达到移除标准,移除后1年无LVAD/移植生存率90%。
  • 该策略在全部6个参与中心均可行且可重复,移除后2年和3年无LVAD/移植生存率均为77%。

核心结论

  • 在非缺血性心肌病晚期心衰患者中,LVAD优化卸载联合标准化药物和功能监测方案可产生较高的LVAD移除率,且可行、可重复。

研究设计与样本

  • 前瞻性多中心非随机研究(RESTAGE-HF),从6个中心纳入40例接受HeartMate II LVAD的慢性晚期非缺血性心肌病心衰患者。
  • 方案包括优化LVAD转速、积极药物治疗,并在降低转速(6000 rpm,无净血流)下定期超声心动图测试自身心肌功能。

主要发现

  • LVAD前患者年龄35.1±10.8岁,67.5%为男性,心衰平均病程20.8±20.6个月,95%需要正性肌力药,20%需要临时机械支持。
  • LVAD前LVEF 14.5±5.3%,舒张末径7.33±0.89 cm,收缩末径6.74±0.88 cm,肺动脉血氧饱和度46.7±9.2%,肺毛细血管楔压26.2±7.6 mm Hg。
  • 40%(16/40)的入组患者达到主要终点(P<0.0001),接受方案者中50%(18/36)在18个月内被移除LVAD。
  • 移除前LVEF 57±8%,舒张末径4.81±0.58 cm,收缩末径3.53±0.51 cm,肺毛细血管楔压8.1±3.1 mm Hg,6000 rpm下肺动脉血氧饱和度63.6±6.8%。
  • 共19例(19/36,52.3%接受方案者)被移除LVAD,移除后1年无LVAD/移植生存率90%,2年和3年均为77%。

临床怎么用

  • 对非缺血性心肌病晚期心衰患者,可考虑LVAD卸载联合标准化药物逆转重构方案以争取心肌恢复和移除装置。
  • 移除前需在降低LVAD转速(6000 rpm,无净血流)下定期评估自身心肌功能,达到移除标准后实施移除。

局限性

  • 本研究为非随机研究,样本量较小(40例),且仅纳入非缺血性心肌病和HeartMate II LVAD患者。
  • 4例入组患者因与研究操作无关的医学并发症未接受方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular assist device (LVAD) unloading and hemodynamic support in patients with advanced chronic heart failure can result in significant improvement in cardiac function allowing LVAD removal; however, the rate of this is generally considered to be low. This prospective multicenter nonrandomized study (RESTAGE-HF [Remission from Stage D Heart Failure]) investigated whether a protocol of optimized LVAD mechanical unloading, combined with standardized specific pharmacological therapy to induce reverse remodeling and regular testing of underlying myocardial function, could produce a higher incidence of LVAD explantation. METHODS: Forty patients with chronic advanced heart failure from nonischemic cardiomyopathy receiving the Heartmate II LVAD were enrolled from 6 centers. LVAD speed was optimized with an aggressive pharmacological regimen, and regular echocardiograms were performed at reduced LVAD speed (6000 rpm, no net flow) to test underlying myocardial function. The primary end point was the proportion of patients with sufficient improvement of myocardial function to reach criteria for explantation within 18 months with sustained remission from heart failure (freedom from transplant/ventricular assist device/death) at 12 months. RESULTS: Before LVAD, age was 35.1±10.8 years, 67.5% were men, heart failure mean duration was 20.8±20.6 months, 95% required inotropic and 20% temporary mechanical support, left ventricular ejection fraction was 14.5±5.3%, end-diastolic diameter was 7.33±0.89 cm, end-systolic diameter was 6.74±0.88 cm, pulmonary artery saturations were 46.7±9.2%, and pulmonary capillary wedge pressure was 26.2±7.6 mm Hg. Four enrolled patients did not undergo the protocol because of medical complications unrelated to the study procedures. Overall, 40% of all enrolled (16/40) patients achieved the primary end point, P<0.0001, with 50% (18/36) of patients receiving the protocol being explanted within 18 months (pre-explant left ventricular ejection fraction, 57±8%; end-diastolic diameter, 4.81±0.58 cm; end-systolic diameter, 3.53±0.51 cm; pulmonary capillary wedge pressure, 8.1±3.1 mm Hg; pulmonary artery saturations 63.6±6.8% at 6000 rpm). Overall, 19 patients were explanted (19/36, 52.3% of those receiving the protocol). The 15 ongoing explanted patients are now 2.26±0.97 years after explant. After explantation survival free from LVAD or transplantation was 90% at 1-year and 77% at 2 and 3 years. CONCLUSIONS: In this multicenter prospective study, this strategy of LVAD support combined with a standardized pharmacological and cardiac function monitoring protocol resulted in a high rate of LVAD explantation and was feasible and reproducible with explants occurring in all 6 participating sites. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01774656.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Birks EJ, Drakos SG, Patel SR, et al. Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results. Circulation. 2020. PMID: 33100036. doi:10.1161/CIRCULATIONAHA.120.046415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。